The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis

Journal of Surgical Oncology

Volumn 114, Issue 7, 2016, Pages 803-809

  Sasaki, Kazunari ^a   Andreatos, Nikolaos ^a   Margonis, Georgios A ^a   He, Jin ^a   Weiss, Matthew ^a   Johnston, Fabian ^a   Wolfgang, Christopher ^a   Antoniou, Efstathios ^b   Pikoulis, Emmanouil ^b   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

CRC; CRLM; left sided; location; prognosis; right sided

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCENDING COLON; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CECUM; COLORECTAL LIVER METASTASIS; COLORECTAL TUMOR; DESCENDING COLON; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER RESECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; SIGMOID; TRANSVERSE COLON; TUMOR LOCALIZATION; ADENOCARCINOMA; ETIOLOGY; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY; STATISTICAL MODEL; SURVIVAL ANALYSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84992469606     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24425     Document Type: Article

References (40)

1. Benedix F, Kube R, Meyer F, et al.: Comparison of 17,641 patients with right- and left-sided colon cancer: Differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010; 53:57–64.
2. Meguid RA, Slidell MB, Wolfgang CL, et al.: Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 2008; 15:2388–2394.
3. Yahagi M, Okabayashi K, Hasegawa H, et al.: The worse prognosis of right-sided compared with left-sided colon cancers: A systematic review and meta-analysis. J Gastrointest Surg 2016; 20:648–655.
4. Gervaz P, Bucher P, Morel P: Two colons-two cancers: Paradigm shift and clinical implications. J Surg Oncol 2004; 88:261–266.
5. Shen H, Yang J, Huang Q, et al.: Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol 2015; 21:6470–6478.
6. Lee GH, Malietzis G, Askari A, et al.: Is right-sided colon cancer different to left-sided colorectal cancer?—A systematic review. Eur J Surg Oncol 2015; 41:300–308.
7. Bufill JA: Colorectal cancer: Evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990; 113:779–788.
8. Nitsche U, Stogbauer F, Spath C, et al.: Right sided colon cancer as a distinct histopathological subtype with reduced prognosis. Dig Surg 2016; 33:157–163.
9. Margonis GA, Kim Y, Spolverato G, et al.: Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg 2015; 150:722–729.
10. Margonis GA, Kim Y, Sasaki K, et al.: Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer 2016; 122:2698–2707.
11. de Jong MC, Pulitano C, Ribero D, et al.: Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients. Ann Surg 2009; 250:440–448.
12. Kulaylat AN, Schubart JR, Stokes AL, et al.: Overall survival by pattern of recurrence following curative intent surgery for colorectal liver metastasis. J Surg Oncol 2014; 110:1011–1015.
13. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999; 230:309–318; discussion 318–321.
14. Pawlik TM, Choti MA: Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Curr Oncol Rep 2007; 9:193–201.
15. Brudvik KW, Kopetz SE, Li L, et al.: Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 2015; 102:1175–1183.
16. Missiaglia E, Jacobs B, D'Ario G, et al.: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014; 25:1995–2001.
17. Lee YC, Lee YL, Chuang JP, et al.: Differences in survival between colon and rectal cancer from SEER data. PLoS ONE 2013; 8:e78709.
18. Iacopetta B: Are there two sides to colorectal cancer? Int J Cancer 2002; 101:403–408.
19. Elias D, Liberale G, Vernerey D, et al.: Hepatic and extrahepatic colorectal metastases: When resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005; 12:900–909.
20. Pai RK, Jayachandran P, Koong AC, et al.: BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: An aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 2012; 36:744–752.
21. Zhang J, Zheng J, Yang Y, et al.: Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: Analysis of 1,110 cases. Sci Rep 2015; 5:18678.
22. Breivik J, Lothe RA, Meling GI, et al.: Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer 1997; 74:664–669.
23. Kodaz H, Hacibekiroglu I, Erdogan B, et al.: Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. Mol Clin Oncol 2015; 3:179–184.
24. Brule SY, Jonker DJ, Karapetis CS, et al.: Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015; 51:1405–1414.
25. Yoon HH, Tougeron D, Shi Q, et al.: KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 2014; 20:3033–3043.
26. Roth AD, Tejpar S, Delorenzi M, et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol 2010; 28:466–474.
27. Karagkounis G, Torbenson MS, Daniel HD, et al.: Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 2013; 119:4137–4144.
28. Umeda Y, Nagasaka T, Mori Y, et al.: Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci 2013; 20:223–233.
29. Schirripa M, Bergamo F, Cremolini C, et al.: BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 2015; 112:1921–1928.
30. Tran B, Kopetz S, Tie J, et al.: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117:4623–4632.
31. Vauthey JN, Zimmitti G, Kopetz SE, et al.: RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258:617–626; discussion 619–627.
32. Tejpar S, Bertagnolli M, Bosman F, et al.: Prognostic and predictive biomarkers in resected colon cancer: Current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010; 15:390–404.
33. Loupakis F, Yang D, Yau L, et al.: Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015; 107.
34. van Erning FN, Elferink MA, Bos AC, et al.: RE: Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015;107.
35. Hagen F, Kennecke CS, Davies JM, et al.: Differences in relapse-free survival (RFS) and survival after relapse (SAR) in right (R) versus left (L) stage I–III colon cancer (CCa) [abstract]. Amerian Society of Clinical Oncology(ASCO) annual meeting: 2016, June 3–7 6/4/2016; Chicago, Illinois(IL) 2016.
36. Sinicrope FA, Mahoney MR, Smyrk TC, et al.: Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013; 31:3664–3672.
37. Modest DP, Schulz C, von Weikersthal LF, et al.: Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): Analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anticancer Drugs 2014; 25:212–218.
38. von Einem JC, Heinemann V, von Weikersthal LF, et al.: Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: An analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 2014; 140:1607–1614.
39. Boisen MK, Johansen JS, Dehlendorff C, et al.: Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 2013; 24:2554–2559.
40. Volz NB, Stintzing S, Zhang W, et al.: Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J 2015; 15:69–76.